Key result
In patients with acute ischemic stroke, hemorrhage occurred in 6.7% of those treated with tirofiban alone, 23.1% with tirofiban plus thrombolysis, and 7.7% with tirofiban plus bridging therapy.
Why the study?
Is tirofiban safe when used alone or in combination with other treatments in patients with acute ischemic stroke?
Observational (n=120)
Is tirofiban safe when used alone or in combination with other treatments in patients with acute ischemic stroke?
Tirofiban appears relatively safe in acute ischemic stroke, though bleeding risk is higher when combined with thrombolytic therapy.
May warrant caution with tirofiban plus thrombolysis due to higher hemorrhage; leaves open monotherapy safety pending randomized trials.
Aim. This work aims to study the safety of tirofiban alone and in combination with various treatments in acute ischemic stroke (AIS). Material and methods. 120 AIS patients were included in this study. There were 3 groups as below: Group A (tirofiban alone, n=68), Group B (tirofiban plus thrombolytic therapy, n=26), and Group C (tirofiban plus bridging therapy, n=26). Risk factors, stroke severity, initial imaging, treatment regimens, complications and longterm outcomes were analyzed. Results . Eight patients (6,7%) in Group A, 6 patients (23,1%) in Group B and 2 patients (7,7%) in Group C had hemorrhage during or after treatment. Sixteen patients (6 in Group A, 8 in Group B and 2 in Group C) died during hospital admission. The mortality rate was 13,3% (8,8% for Group A, 30,7% for Group B and 7,7% for Group C, respectively) in the acute phase. A favorable outcome (mRS 0–2) at the first three months after stroke was only observed in 43,3% of patients (44,1% in Group A, 46,7% in Group B and 36,4% in Group C). The average Barthel index was 72,3 in Group A, 84,4 in Group B and 56,8 in Group C (total score: 71,0). Conclusion. The stroke treatment with tirofiban is safe in AIS. A large randomized controlled trial in the future will be needed to decrease the minor bleeding complication of tirofiban therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) conducted an observational in Acute ischemic stroke (AIS) (n=120). Tirofiban alone or in combination with other treatments was evaluated on Hemorrhage during or after treatment. In patients with acute ischemic stroke, hemorrhage occurred in 6.7% of those treated with tirofiban alone, 23.1% with tirofiban plus thrombolysis, and 7.7% with tirofiban plus bridging therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: